Job title: Co-Founder & Chief Science Officer
Erica Barnell, PhD is the co-founder and Chief Science Officer of Geneoscopy, a St. Louis healthcare startup company that is building diagnostics to noninvasively diagnose, monitor, and treat gastrointestinal disease. Dr. Barnell has published 18 peer-review manuscripts within the field of precision oncology, has written a book chapter on tumor heterogeneity, and is an inventor on three patents related to Geneoscopy’s technology. At Geneoscopy, Erica is currently working towards obtaining FDA approval for Geneoscopy’s lead assay, which is a non-invasive test that can detect both colorectal cancer and advanced adenomas in average-risk individuals over the age of 45. This test was awarded Breakthrough Device Designation status from the FDA for its novel ability to detect advanced adenomas with high sensitivity. Dr. Barnell has built a CAP/CLIA certified laboratory and has engaged in multiple collaborations with pharmaceutical companies to build pipeline products. Dr. Barnell was awarded the scholar-in-training award in 2019 by both the Cancer Genomics Consortium and the American Association of Cancer Research. In 2020, she was honored to be named to the Forbes 30 Under 30 list and spoke at the 2020 Forbes Healthcare Virtual Summit.
Numerous Applications of Stool Derived Eukaryotic RNA (seRNA) Biomarkers to Non-invasively Assess Gastrointestinal Disease 1:30 pm
Improving detection, monitoring, and measurement of treatment response for patients with GI diseases, including CRC and IBD Refining clinically relevant biomarker panels using eukaryotic RNA from gastrointestinal enterocytes, resident lymphocytes, and the hostmicrobiome interaction Leveraging technology across a variety of biomarker types, including RNA expression, allele frequencies of expressed RNA variants, and protein concentrationsRead more
day: Day One